Glucoraphanin vs. sulforaphane: what ingredient buyers should compare

1. Define the material before comparing the percentage

A purchasing brief that says only ‘broccoli extract, high strength’ leaves several decisions unresolved. The material might be specified by glucoraphanin, preformed sulforaphane, or a conversion system combining a precursor with an enzyme. These are different inputs, even when all are sold under the same botanical name.

Ask the supplier to identify the plant species and part, the marker compound, the analytical method and whether the result applies to the powder as supplied or a dry basis. Also identify every carrier or other ingredient. A marker result belongs to that defined material; it is not automatically a result for a finished capsule or beverage.

2. What a human crossover study actually measured

In a 2011 crossover trial, Egner and colleagues studied two broccoli-sprout beverages in 50 participants. One was glucoraphanin-rich; the other had been treated with myrosinase to provide sulforaphane. Mean urinary recovery of sulforaphane and its metabolites was approximately 5% and 70%, respectively, in collections of roughly 12 hours after dosing. The study used two seven-day administration periods separated by a five-day washout. Publisher DOI; PubMed record and abstract.

These were different study preparations and input amounts, not equal masses of two commercial powders. The inputs are reported to interpret the experiment; they are not recommended doses. The chart retains the publication’s urinary-recovery endpoint rather than treating it as a clinical-efficacy score.

This is a comparison of the study preparations and its urinary endpoint. It is not evidence that an arbitrary supplier’s extract achieves either value. Nor is urinary recovery a demonstrated clinical benefit. The chart should prompt better formulation questions, rather than a ‘14 times better’ sales claim.

3. Make the enzyme question part of the specification

If your development strategy includes conversion of a precursor, request a description of the complete system. Identify where the enzyme comes from, how activity is expressed, which analytical conditions were used and whether the material will encounter heat, moisture or acidity during manufacture. A statement that an enzyme was added is not a measurement of its retained activity.

Ask whether supporting work tested the purchased powder, a model mixture, or the intended finished format. Keep those evidence levels separate in the project file. A later study by Fahey and colleagues specifically examined active endogenous myrosinase in broccoli preparations; it is relevant background for designing questions, but does not qualify an unrelated commercial batch. See the 2015 study.

4. Turn the comparison into a useful RFQ

Send the same technical brief to each candidate supplier. State the intended dosage form and processing conditions, desired analyte and assay basis, target purchase quantity, delivery destination and documents needed for evaluation. Ask for a representative sample linked to its lot records, then define which release tests your team will apply.

• Material: botanical identity, seed or sprout source, carriers and other ingredients.
• Assay: named analyte, method, unit, basis and whether a value is measured or potential.
• System: enzyme identity and activity where relevant, with storage conditions.
• Evidence: distinguish ingredient tests, finished-format tests and published studies.
• Commercial terms: sample quantity, MOQ, packaging, lead time and quote validity.

Where specifications differ, ask for clarification before calculating a price comparison. A lower price per kilogram may simply describe a different material. Do not convert glucoraphanin mass directly into sulforaphane mass without an explicit chemical and conversion basis.

5. Record the basis for your material choice

There is no universal winner independent of the intended product. Compare the requirements your formulation and quality teams can verify: the incoming material, the manufacturing process, the stability program and the finished-format performance. Document the rationale and any unresolved assumptions before a purchase order is approved.

For a first discussion, a clearly stated requirement is more useful than asking for the ‘strongest’ extract. If the commercial documentation cannot distinguish precursor content from preformed compound or potential yield, pause the comparison and resolve that terminology first.